Yes, acyclovir 800 mg PO BID is an appropriate and guideline-supported regimen for recurrent genital herpes simplex infection.
Acyclovir 800 mg orally twice daily for 5 days is explicitly recommended as one of several equivalent first-line treatment options for episodic recurrent genital HSV infection 1, 2.
Clinical Context and Dosing Options
The most recent European Association of Urology (2026) guidelines clearly list acyclovir 800 mg BID for 5 days as a standard treatment regimen for recurrent genital HSV 1. This is consistent with long-standing CDC recommendations from 1998 that established this dose as equivalent to other regimens 2.
For Recurrent Episodes (Episodic Treatment):
You have three equally effective acyclovir options 1, 2:
- 800 mg BID for 5 days (your proposed regimen)
- 400 mg TID for 5 days
- 800 mg TID for 2 days (shortest course)
For First Clinical Episode:
Higher frequency dosing is required 1:
- 400 mg TID for 10 days, OR
- 200 mg five times daily for 10 days
For Suppressive Therapy (≥6 recurrences/year):
- 400 mg BID continuously 2
Key Clinical Considerations
Timing is critical: Treatment should be initiated at the first sign of prodrome or within 1 day of lesion onset for maximum benefit 2. Many patients benefit from having a prescription available to self-initiate therapy immediately when symptoms begin.
The 800 mg BID regimen offers distinct advantages:
- Improved adherence compared to five-times-daily dosing 3, 4
- Equivalent efficacy to more frequent dosing schedules 3, 4
- May be more effective than 200 mg five times daily for treating existing vesicular lesions, particularly in male patients 3, 4
Important Caveats
Renal function matters: Dosage adjustment is required in patients with renal impairment 5. Maintain adequate hydration during treatment 5.
Patient counseling is essential 2:
- Acyclovir is not a cure and does not prevent transmission
- Avoid sexual contact when lesions or symptoms are present
- Transmission can occur during asymptomatic viral shedding
- Recurrence frequency typically decreases over time
Immunocompromised patients may require more aggressive therapy or IV administration for severe disease 2, 6. Watch for acyclovir-resistant strains in this population, though resistance remains uncommon in immunocompetent patients 7.
Severe disease requiring hospitalization (disseminated infection, encephalitis, pneumonitis, hepatitis) necessitates IV acyclovir 5-10 mg/kg every 8 hours 1, 2.
Safety Profile
The regimen is well-tolerated with minimal adverse effects. Common side effects include nausea (2.7%), diarrhea, and headache 5. Serious adverse events are rare but include renal dysfunction (particularly with inadequate hydration), CNS symptoms in elderly or renally impaired patients, and hypersensitivity reactions 5.